Geneos Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series A3
- Latest Deal Amount
-
$10M
- Investors
-
7
Geneos Therapeutics General Information
Description
Developer of neo-antigen-based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop cancer treatments, enabling oncologists to have access to tumor-targeted immunotherapies to cure patients suffering from multiple types of cancers.
Contact Information
Website
www.geneostx.comCorporate Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
Corporate Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
Geneos Therapeutics Timeline
Geneos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A3) | 27-Sep-2023 | $10M | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC (Series A2) | 21-Mar-2022 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A1) | 12-Nov-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 21-Feb-2019 | $10.5M | $10.5M | Completed | Pre-Clinical Trials | |
| 1. Spin-Off | 01-Aug-2016 | Completed | Startup |
Geneos Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | 5,666,791 | $0.000010 | 8% | $2.12 | $2.12 | 1x | $2.12 | 17.77% |
| Series A | 7,924,523 | $0.000010 | 8% | $1.32 | $1.32 | 1x | $1.32 | 24.85% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Geneos Therapeutics Comparisons
Industry
Financing
Details
Geneos Therapeutics Competitors (27)
One of Geneos Therapeutics’s 27 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Citryll | Venture Capital-Backed | Oss, Netherlands | ||||
| Nouscom | Venture Capital-Backed | Basel, Switzerland | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Cogent Biosciences | Formerly VC-backed | Waltham, MA |
Geneos Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Geneos Therapeutics Patents
Geneos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023269389-A1 | Individualized cancer epitopes and methods of using the same | Pending | 10-May-2022 | ||
| AU-2023267771-A1 | Vaccines and methods of using the same to treat wnt-related cancer | Pending | 10-May-2022 | ||
| EP-4522207-A1 | Individualized cancer epitopes and methods of using the same | Pending | 10-May-2022 | ||
| EP-4522752-A1 | Vaccines and methods of using the same to treat wnt-related cancer | Pending | 10-May-2022 | ||
| EP-3801597-A4 | Tumor-specific neoantigens and methods of using the same | Pending | 25-May-2018 | C07K14/4748 |
Geneos Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Geneos Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3B Future Health Fund | Venture Capital | Minority | ||
| Shanghai Healthcare Capital | PE/Buyout | Minority | ||
| Flerie | Venture Capital | Minority | ||
| Korea Investment Partners | Venture Capital | Minority | ||
| Global BIO Impact Fund | Other | Minority |
Geneos Therapeutics FAQs
-
When was Geneos Therapeutics founded?
Geneos Therapeutics was founded in 2016.
-
Where is Geneos Therapeutics headquartered?
Geneos Therapeutics is headquartered in Philadelphia, PA.
-
What is the size of Geneos Therapeutics?
Geneos Therapeutics has 10 total employees.
-
What industry is Geneos Therapeutics in?
Geneos Therapeutics’s primary industry is Drug Discovery.
-
Is Geneos Therapeutics a private or public company?
Geneos Therapeutics is a Private company.
-
What is the current valuation of Geneos Therapeutics?
The current valuation of Geneos Therapeutics is .
-
What is Geneos Therapeutics’s current revenue?
The current revenue for Geneos Therapeutics is .
-
How much funding has Geneos Therapeutics raised over time?
Geneos Therapeutics has raised $49.7M.
-
Who are Geneos Therapeutics’s investors?
3B Future Health Fund, Shanghai Healthcare Capital, Flerie, Korea Investment Partners, and Global BIO Impact Fund are 5 of 7 investors who have invested in Geneos Therapeutics.
-
Who are Geneos Therapeutics’s competitors?
NexImmune, Citryll, Nouscom, TScan Therapeutics, and Cogent Biosciences are some of the 27 competitors of Geneos Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
